Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBT (2016 - 2025)

Historic EBT for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $1.0 million.

  • OptimizeRx's EBT rose 11055.23% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 10505.82%. This contributed to the annual value of -$19.4 million for FY2024, which is 2296.53% up from last year.
  • Per OptimizeRx's latest filing, its EBT stood at $1.0 million for Q3 2025, which was up 11055.23% from $1.7 million recorded in Q2 2025.
  • OptimizeRx's EBT's 5-year high stood at $2.2 million during Q4 2024, with a 5-year trough of -$11.7 million in Q4 2023.
  • Its 5-year average for EBT is -$3.0 million, with a median of -$3.3 million in 2025.
  • In the last 5 years, OptimizeRx's EBT tumbled by 879000.85% in 2022 and then soared by 13361.46% in 2025.
  • Quarter analysis of 5 years shows OptimizeRx's EBT stood at $623462.0 in 2021, then plummeted by 152.26% to -$325836.0 in 2022, then crashed by 3503.04% to -$11.7 million in 2023, then soared by 118.81% to $2.2 million in 2024, then tumbled by 52.49% to $1.0 million in 2025.
  • Its EBT was $1.0 million in Q3 2025, compared to $1.7 million in Q2 2025 and -$3.3 million in Q1 2025.